Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, enhancing the company's expertise in biotechnology, drug delivery, and central nervous system clinical development. The additions come as the company advances its pipeline of novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.
Dr. Robert Langer is a renowned figure in biotechnology and drug delivery, with over 1,500 patents worldwide and numerous awards, including the National Medal of Science. His work at the Massachusetts Institute of Technology has pioneered controlled-release drug delivery systems. Dr. Stephen Brannan brings deep experience in CNS clinical development, having led numerous psychiatric drug programs. Their insights are expected to support Helus Pharma's disciplined, evidence-based approach to drug development.
The company is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. These programs target large unmet needs in mental health, where existing treatments often have limited efficacy or significant side effects.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, aims to improve the treatment landscape through NSAs that may provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's website at www.helus.com.
The addition of Dr. Langer and Dr. Brannan to the Scientific Advisory Board signals a commitment to rigorous science and could accelerate the development of Helus Pharma's pipeline. Their expertise may enhance the company's ability to navigate complex clinical trials and regulatory pathways, potentially bringing new treatments to patients suffering from depression and anxiety. This move underscores the importance of combining innovative drug design with seasoned guidance in the competitive biotech landscape.